Matthew Ronsheim - Xenon Pharmaceuticals Chief Officer
| XENE Stock | USD 41.48 0.14 0.34% |
Executive
Matthew Ronsheim is Chief Officer of Xenon Pharmaceuticals
| Age | 54 |
| Address | 200-3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8 |
| Phone | 604 484 3300 |
| Web | https://www.xenon-pharma.com |
Xenon Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2951) % which means that it has lost $0.2951 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4514) %, meaning that it created substantial loss on money invested by shareholders. Xenon Pharmaceuticals' management efficiency ratios could be used to measure how well Xenon Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of February 14, 2026, Return On Tangible Assets is expected to decline to -0.35. In addition to that, Return On Capital Employed is expected to decline to -0.44. At present, Xenon Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 9.1 M, whereas Return On Tangible Assets are forecasted to decline to (0.35).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| ACIS ACS | Ascentage Pharma Group | 42 | |
| Matthew JD | Apogee Therapeutics Common | 50 | |
| Raphael CPA | Centessa Pharmaceuticals PLC | 47 | |
| Thomas JD | Ascentage Pharma Group | 73 | |
| Amy Steele | CG Oncology Common | N/A | |
| Joshua Patterson | CG Oncology Common | 50 | |
| Erik MBA | Ultragenyx | 56 | |
| JD III | Zai Lab | 60 | |
| Eric Huang | Ascentage Pharma Group | N/A | |
| Edward MBA | Scholar Rock Holding | 53 | |
| MBA MD | Celcuity LLC | N/A | |
| Robert Woods | Scholar Rock Holding | 58 | |
| Harris Rotman | Centessa Pharmaceuticals PLC | N/A | |
| Tong Zhu | Zai Lab | 48 | |
| Chongdong Fu | Ascentage Pharma Group | N/A | |
| Joanne Choi | Legend Biotech Corp | N/A | |
| Catherine Hu | Scholar Rock Holding | N/A | |
| Sarah Connors | CG Oncology Common | N/A | |
| Carlos Santos | Legend Biotech Corp | N/A | |
| Caroline Paul | Legend Biotech Corp | N/A | |
| Raymond Kmetz | Ascentage Pharma Group | 66 | |
Management Performance
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.3 |
Xenon Pharmaceuticals Leadership Team
Elected by the shareholders, the Xenon Pharmaceuticals' board of directors comprises two types of representatives: Xenon Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xenon. The board's role is to monitor Xenon Pharmaceuticals' management team and ensure that shareholders' interests are well served. Xenon Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xenon Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CMA CPA, CEO Pres | ||
| Darren MBA, Chief Team | ||
| Christopher MD, Chief Officer | ||
| MBA MSc, Ex Operations | ||
| J Gilbert, Senior Director | ||
| Colleen Alabiso, Senior Affairs | ||
| MBA MPH, Chief Officer | ||
| Sherry Aulin, Chief Officer | ||
| Andrea JD, Chief Secretary | ||
| Robin Sherrington, Sr. VP of Bus. and Corporate Devel. | ||
| Thomas JD, Chief Officer | ||
| Matthew Ronsheim, Chief Officer | ||
| Shelley BA, Executive Resources | ||
| James Empfield, Senior Vice President - Drug Discovery |
Xenon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xenon Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (45.44) % | ||||
| Current Valuation | 2.76 B | ||||
| Shares Outstanding | 77.28 M | ||||
| Shares Owned By Insiders | 0.10 % | ||||
| Shares Owned By Institutions | 99.90 % | ||||
| Number Of Shares Shorted | 5.54 M | ||||
| Price To Earning | (1.75) X | ||||
| Price To Book | 5.74 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Xenon Pharmaceuticals is a strong investment it is important to analyze Xenon Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Xenon Pharmaceuticals' future performance. For an informed investment choice regarding Xenon Stock, refer to the following important reports:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Will Biotechnology sector continue expanding? Could Xenon diversify its offerings? Factors like these will boost the valuation of Xenon Pharmaceuticals. Anticipated expansion of Xenon directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Xenon Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.89) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Understanding Xenon Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Xenon's accounting equity. The concept of intrinsic value - what Xenon Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Xenon Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Xenon Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.